Aron Gyorgypal | PhD Candidate, Chemical and Biochemical Engineering
Rutgers University

Aron Gyorgypal, PhD Candidate, Chemical and Biochemical Engineering, Rutgers University

Aron Gyorgypal is a Ph.D. Candidate in the Chemical and Biochemical Engineering Department at Rutgers University (New Jersey, USA). His research focuses on novel PAT development and implementation for continuous bioprocessing of mammalian cultures (CHO) to produce biotherapeutics, such as monoclonal antibodies (mAbs). His work has led to the development of the N-GLYcanyzer PAT system: which enables real-time monitoring of mAb N-glycosylation. His now looks to explore antibody glycosylation dynamics during bioprocessing to allow for a better understanding of protein quality and the design space. He received his bachelor's in chemical engineering from the New Jersey Institute of Technology (NJIT) in 2018 and is currently pursuing his Ph.D. in Chemical and Biochemical Engineering.

The Chundawat Research Group at Rutgers University takes a carbohydrate or ‘glycan-centric’ approach to sustainably address relevant problems in the broad areas of bioenergy, biopharmaceutical, biomedical, biomaterials, and bioseparations engineering. The group develops and applies protein and glycan engineering (or glycoengineering), bioprocessing, and biophysical techniques to address fundamental engineering problems centered on carbohydrates. Chundawat’s research team at Rutgers is actively working towards expanding the repertoire of applications for carbohydrate-active enzymes and glycans in general in the area of biomanufacturing and human health, in particular.

Appearances:



Festival of Biologics Day 2 @ 15:40

Enabling Monoclonal Antibody N-Linked Glycosylation Monitoring during Upstream Bioprocessing

The biopharmaceutical industry is transitioning towards continuous biomanufacturing processes that require advanced analytical tools to monitor and control bioprocesses to produce high-quality biologics. Post-translational modification of therapeutic proteins, such as N-linked glycosylation, are critical quality attributes that affect biologics safety and efficacy, requiring close monitoring during biomanufacturing. We have developed an analytical toolkit to monitor monoclonal antibody N-linked glycosylation. Here we highlight this toolkit and provide examples of its use for monitoring an upstream process for producing a commercially relevant Trastuzumab biosimilar.

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers